225 related articles for article (PubMed ID: 34723633)
1. Protamine Sulfate Is a Potent Inhibitor of Human Papillomavirus Infection
Young JM; Zine El Abidine A; Gómez-Martinez RA; Bondu V; Sterk RT; Surviladze Z; Ozbun MA
Antimicrob Agents Chemother; 2022 Jan; 66(1):e0151321. PubMed ID: 34723633
[TBL] [Abstract][Full Text] [Related]
2. Carrageenan is a potent inhibitor of papillomavirus infection.
Buck CB; Thompson CD; Roberts JN; Müller M; Lowy DR; Schiller JT
PLoS Pathog; 2006 Jul; 2(7):e69. PubMed ID: 16839203
[TBL] [Abstract][Full Text] [Related]
3. Spectrum of genital human papillomavirus infection in a female adolescent population.
Jamison JH; Kaplan DW; Hamman R; Eagar R; Beach R; Douglas JM
Sex Transm Dis; 1995; 22(4):236-43. PubMed ID: 7482107
[TBL] [Abstract][Full Text] [Related]
4. Human papillomavirus type 31b infection of human keratinocytes does not require heparan sulfate.
Patterson NA; Smith JL; Ozbun MA
J Virol; 2005 Jun; 79(11):6838-47. PubMed ID: 15890923
[TBL] [Abstract][Full Text] [Related]
5. Vimentin Modulates Infectious Internalization of Human Papillomavirus 16 Pseudovirions.
Schäfer G; Graham LM; Lang DM; Blumenthal MJ; Bergant Marušič M; Katz AA
J Virol; 2017 Aug; 91(16):. PubMed ID: 28566373
[TBL] [Abstract][Full Text] [Related]
6. Characterization of serum antibodies from women immunized with Gardasil: A study of HPV-18 infection of primary human keratinocytes.
Wang HK; Wei Q; Moldoveanu Z; Huh WK; Vu HL; Broker TR; Mestecky J; Chow LT
Vaccine; 2016 Jun; 34(27):3171-3177. PubMed ID: 27113165
[TBL] [Abstract][Full Text] [Related]
7. Chondroitin Sulfate Proteoglycans Are De Facto Cellular Receptors for Human Papillomavirus 16 under High Serum Conditions.
Fons NR; Kines RC; Thompson CD; Day PM; Lowy DR; Schiller JT
J Virol; 2022 Apr; 96(7):e0185721. PubMed ID: 35285688
[TBL] [Abstract][Full Text] [Related]
8. Genitoanal human papillomavirus infection and associated neoplasias.
Gross G
Curr Probl Dermatol; 2014; 45():98-122. PubMed ID: 24643181
[TBL] [Abstract][Full Text] [Related]
9. [HPV vaccination and the prevention of genital warts and precancerous lesions-current evidence and evaluation].
Osmani V; Klug SJ
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2021 May; 64(5):590-599. PubMed ID: 33851224
[TBL] [Abstract][Full Text] [Related]
10. Epidemiology and natural history of genital human papillomavirus infection.
Weaver BA
J Am Osteopath Assoc; 2006 Mar; 106(3 Suppl 1):S2-8. PubMed ID: 16729554
[TBL] [Abstract][Full Text] [Related]
11. Impact of inhibitors and L2 antibodies upon the infectivity of diverse alpha and beta human papillomavirus types.
Kwak K; Jiang R; Wang JW; Jagu S; Kirnbauer R; Roden RB
PLoS One; 2014; 9(5):e97232. PubMed ID: 24816794
[TBL] [Abstract][Full Text] [Related]
12. HPV entry into cells.
Aksoy P; Gottschalk EY; Meneses PI
Mutat Res Rev Mutat Res; 2017; 772():13-22. PubMed ID: 28528686
[TBL] [Abstract][Full Text] [Related]
13. Oral immunization with bacteriophage MS2-L2 VLPs protects against oral and genital infection with multiple HPV types associated with head & neck cancers and cervical cancer.
Zhai L; Yadav R; Kunda NK; Anderson D; Bruckner E; Miller EK; Basu R; Muttil P; Tumban E
Antiviral Res; 2019 Jun; 166():56-65. PubMed ID: 30926288
[TBL] [Abstract][Full Text] [Related]
14. Sulfated K5 Escherichia coli polysaccharide derivatives as wide-range inhibitors of genital types of human papillomavirus.
Lembo D; Donalisio M; Rusnati M; Bugatti A; Cornaglia M; Cappello P; Giovarelli M; Oreste P; Landolfo S
Antimicrob Agents Chemother; 2008 Apr; 52(4):1374-81. PubMed ID: 18250186
[TBL] [Abstract][Full Text] [Related]
15. HPV infection in women: psychosexual impact of genital warts and intraepithelial lesions.
Graziottin A; Serafini A
J Sex Med; 2009 Mar; 6(3):633-45. PubMed ID: 19170869
[TBL] [Abstract][Full Text] [Related]
16. Developments in L2-based human papillomavirus (HPV) vaccines.
Schellenbacher C; Roden RBS; Kirnbauer R
Virus Res; 2017 Mar; 231():166-175. PubMed ID: 27889616
[TBL] [Abstract][Full Text] [Related]
17. Epidemiology and natural history of human papillomavirus infections in the female genital tract.
Ault KA
Infect Dis Obstet Gynecol; 2006; 2006 Suppl():40470. PubMed ID: 16967912
[TBL] [Abstract][Full Text] [Related]
18. Broad Cross-Protection Is Induced in Preclinical Models by a Human Papillomavirus Vaccine Composed of L1/L2 Chimeric Virus-Like Particles.
Boxus M; Fochesato M; Miseur A; Mertens E; Dendouga N; Brendle S; Balogh KK; Christensen ND; Giannini SL
J Virol; 2016 Jul; 90(14):6314-25. PubMed ID: 27147749
[TBL] [Abstract][Full Text] [Related]
19. Characteristics of carcinogenic human papillomavirus infection in Suzhou: Epidemiology, vaccine evaluation, and associated diseases.
Li WJ; Xu HX; Chen ZH; Xu WD; Wu YJ
J Med Virol; 2017 May; 89(5):895-901. PubMed ID: 27696465
[TBL] [Abstract][Full Text] [Related]
20. Annual disease burden due to human papillomavirus (HPV) 6 and 11 infections in Finland.
Syrjänen KJ
Scand J Infect Dis Suppl; 2009; 107():3-32. PubMed ID: 19408160
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
